533734
1,3-Propanediol
≥99.6%
Synonym(s):
1,3-Dihydroxypropane, Trimethylene glycol
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
HO(CH2)3OH
CAS Number:
Molecular Weight:
76.09
EC Number:
207-997-3
UNSPSC Code:
12162002
PubChem Substance ID:
Beilstein/REAXYS Number:
969155
MDL number:
vapor pressure
0.8 mmHg ( 20 °C), 9.8 mmHg ( 100 °C)
assay
≥99.6%
impurities
<0.1% water
refractive index
n20/D 1.440 (lit.)
surface tension
46.2 dyn/cm, 20 °C
viscosity
52 cP(20 °C)(lit.)
bp
214 °C/760 mmHg (lit.)
mp
−27 °C (lit.)
solubility
H2O: soluble
density
1.053 g/mL at 25 °C (lit.)
anion traces
chloride (Cl-): <0.5 ppm
SMILES string
OCCCO[H]
InChI
1S/C3H8O2/c4-2-1-3-5/h4-5H,1-3H2
InChI key
YPFDHNVEDLHUCE-UHFFFAOYSA-N
Application
For applications, see P5040-4
Still not finding the right product?
Explore all of our products under 1,3-Propanediol
Storage Class
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
E Celińska
Biotechnology advances, 28(4), 519-530 (2010-04-07)
The history of 1,3-propanediol (1,3-PD) conversion from being a specialty chemical to being a bulk chemical illustrates that the concerted effort of different metabolic engineering approaches brings the most successful results. In order to metabolically tailor the 1,3-PD production pathway
Sarbjit S Saini et al.
The Journal of investigative dermatology, 135(1), 67-75 (2014-07-22)
ASTERIA I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous omalizumab as add-on therapy for 24 weeks in patients with chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained symptomatic despite H1 antihistamine treatment at
Ryosuke Kikuchi et al.
Nature medicine, 20(12), 1464-1471 (2014-11-05)
Peripheral artery disease (PAD) generates tissue ischemia through arterial occlusions and insufficient collateral vessel formation. Vascular insufficiency in PAD occurs despite higher circulating levels of vascular endothelial growth factor A (VEGF-A), a key regulator of angiogenesis. Here we show that